CTRI/2019/02/017428尚未招募1 期
A randomized, double-blind, three-treatment, single intravenous infusion dose, parallel group, bioequivalence study of biosimilar Bevacizumab of Intas Pharmaceuticals Limited, India with Avastinâ?¢ in normal, healthy, adult, human, male subjects.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Normal, healthy, male, adult, human, male subjects between 18 to 45 years of age (both inclusive) with a body mass index (BMI) within the range of 18 to 30 kg per meter square and having a body weight greater than 50 kg.
- •2. Not having any significant disease or abnormal findings during screening, medical history, clinical examination, vital sign examination (Pulse rate, blood pressure, Respiratory rate and temperature), laboratory evaluations, 12-lead ECG and X-ray chest
- •3. Capable of communicating effectively with study personnel.
- •4. Has the willingness to adhere to the protocol requirements.
- •5. Subjects should be willing to use adequate contraception and not donate sperm from admission until 6 months post dosing.
- •6. Able to understand and give written informed consent for participation in the trial.
排除标准
- •1. Known hypersensitivity to the study drug or its constituents.
- •2. Earlier treatment with an anti-VEGF antibody or any other antibody or protein targeting the VEGF receptor (bevacizumab, ranibizumab or related products).
- •3. A recent history of harmful use of alcohol, i.e. alcohol consumption of more than 14 standard drinks per week for men (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40 percentage distilled spirits, such as rum, whisky, brandy etc.) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine.
- •4. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •5. Donation of blood (1 unit or 350 mL) or plasma or equivalent or has undergone surgery in the last 3 months prior to dosing.
- •6. Current Smoker, or was a smoker within last six months prior to start of the study.
- •7. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B (HBsAg, HBcIgM), hepatitis C, or HIV antibody (I & II) found during medical screening.
- •8. Receipt of an investigational medicinal product or participation in a drug research study within a period of 180 days prior to the first dose of study medication.
- •9. History or presence of other systemic disorders or diseases (e.g., hemopoietic, renal, hepatic, cardiovascular, respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement).
- •10. Significant illness within two (2) weeks prior to initial dosing.
- •11. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •12. Subject who underwent surgery and/or suturing for dental procedure or wound dehiscence within 90 days of dosing. Subject who are required to undergo any surgery or dental procedure during the conduct of the study.
- •13. Subjects with history of fracture.
- •14. Subject with history of bleeding disorders, thromboembolic condition, gastrointestinal perforations or any fistulae.
- •15. History of cerebrovascular accidents, transient ischaemic attacks, and myocardial infarction.
- •16. A history of difficulty in donating blood.
- •17. Using anticoagulant drugs, or anti-platelet drugs (Aspirin, NSAID etc.), or history of haemoptysis, thrombotic or haemorrhagic events in the past 6 months.
- •18. Ingestion or use of any prescribed medication at any time within 1 month prior to dosing. Receipt of over-the-counter medicines which have not yet cleared from the body (five half-lives must have passed for the medicine to be considered to have cleared from the body).
- •19. Treated with a vaccine in the last 3 months or a monoclonal antibody in the last 12 months.
- •20. Subject with hypertension (defined as systolic BP of greater than 140 mmHg and diastolic BP of less than 90 mmHg).
- •21. Subjects with proteinuria.
- •22. Any clinically significant laboratory finding at the time of screening
- •23. Consumption of grape fruit or grape fruit products within 72 hours prior to dosing
研究者
相似试验
进行中（未招募）
Unknown
A single dose three-way crossover oral bioavailability study of ß-alanine capsules in comparison with conventional ß-alanine in healthy human volunteers in fasting conditionsCTRI/2024/03/063457atural Alternatives International
招募中
不适用
A randomized, double-blind, single-dose, 3-way, parallel group, comparator-controlled, adaptive design, pharmacokinetic, safety, and tolerability study in healthy male volunteers to evaluate bioequivalence of CBT124 to Avastin(Registered Trademark) (EU and US)non-squamous non-small cell lung cancermetastatic colorectal cancerCancer - Lung - Non small cellCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12616000428460Cipla BioTec Pvt. Ltd.150
尚未招募
1 期
A study comparing the study drug BP02 and Herceptin® in healthy men.HER2 Positive TumoursCancer - Any cancerACTRN12621000573853CuraTeQ Biologics Private Limited111
尚未招募
不适用
A study to assess the bio availability of BCO-5 in comparison with unformulated extracts in healthy volunteers.CTRI/2022/11/047533Akay Natural Ingredients Pvt Ltd
进行中（未招募）
1 期
A trial to investigate the efffect of a SGLT-2 inhibitor a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on glucagon levels, endogenous glucose production and lipolysis.Diabetes mellitus type 2MedDRA version: 19.0Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 100000004861EUCTR2015-004637-27-ATMedizinische Universität Graz18